Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+23.0%
基準 45.25Target55.6
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Key initiatives
01Increased demand for nucleic acid extraction reagents and consumables
02Planned launch of 2 new ODM products
Plan assumptionsNucleic acid extraction reagents and consumables to grow by approximately 10% annually
Segment targetSegment 核酸抽出試薬・消耗品 / Target 毎年約10%成長 / Timing Each year, Segment 新規ODM製品 / Target 2機種上市 / Timing Scheduled
Non-financial targetsIndicator 新規ODM製品の上市数 / Target value 2機種 / Timing Scheduled
Size of the Target MarketSales value [Million US＄]として2020年～2030年の市場推移を図示。出典はNot disclosed。
| Item | Details |
|---|---|
| Plan name | Explanatory Material on Business Plans and Growth Potential |
| Plan period | FY24/6～FY28/6 |
| Progress against the plan | Annual update |
| Sales Target | 45.25（FY24/6） → 55.64（FY28/6） |
| Segment target | Segment 核酸抽出試薬・消耗品 / Target 毎年約10%成長 / Timing Each year, Segment 新規ODM製品 / Target 2機種上市 / Timing Scheduled |
| Non-financial targets | Indicator 新規ODM製品の上市数 / Target value 2機種 / Timing Scheduled |
| Plan assumptions | Nucleic acid extraction reagents and consumables to grow by approximately 10% annually |
| Key initiatives | Increased demand for nucleic acid extraction reagents and consumables, Planned launch of 2 new ODM products |
| Size of the Target Market | Sales value [Million US＄]として2020年～2030年の市場推移を図示。出典はNot disclosed。 |
Items this document does not state (16)
Operating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorResults under the previous planReason for revision or withdrawalRisks identifiedDate of board resolutionPublication date
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、核酸抽出試薬・消耗品の需要増加、同製品が毎年約10％成長する見込み、新規ODM製品2機種の上市予定を挙げている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.